Loading…
Reliance Pharma Fund
Disclosed for 84 months, Sep 2012 to Aug 2019. This scheme is no longer reporting.Published as: RELIANCE PHARMA FUND (An Open Ended Equity Scheme Investing In Pharma Sector)
Portfolio value
₹1,321 Cr
up ₹77.6 Cr vs Jun 2015
- Stocks held
- 14
- up 1 vs Jun 2015
Reliance Pharma Fund is an active equity fund in the Sectoral / Thematic category from Nippon India Mutual Fund. In July 2015 it disclosed 14 stocks worth ₹1,321 Cr, up ₹77.6 Cr from Jun 2015. Its largest positions were Abbott India Limited (12.9%), Sun Pharmaceutical Industries Limited (12.1%), Sanofi India Limited (10.6%); the ten largest together made up 89.9% of the portfolio, and Pharmaceuticals & Biotechnology was the biggest sector at 95.6% of its equity. Cash and debt stood at 1.9%. Compared with Jun 2015 the fund entered 1 new stock and exited 0.
Against 227 other Sectoral / Thematic funds
Concentration
100%
Top-10 weight is higher than 100% of peers
Breadth
2%
Holds more stocks than 2% of peers
Cash
29%
Holds more cash than 29% of peers
What these mean: concentration · cash
Holdings in July 2015
Download CSVEvery line the fund disclosed, with the change against Jun 2015. Click a column to sort; click a company to see every fund that owns it. New to these? How to read a portfolio.
| Abbott India Limited | 12.90% | up 0.77 pts | ₹170 Cr | up ₹19.6 Cr | Added |
| Sun Pharmaceutical Industries Limited | 12.14% | down 1.58 pts | ₹160 Cr | down ₹10.2 Cr | Trimmed |
| Sanofi India Limited | 10.62% | up 1.73 pts | ₹140 Cr | up ₹29.7 Cr | Added |
| Divi's Laboratories Limited | 9.50% | down 0.17 pts | ₹126 Cr | up ₹5.2 Cr | Added |
| Zydus Lifesciences Limited | 9.21% | down 0.21 pts | ₹122 Cr | up ₹4.5 Cr | Added |
| Lupin Limited | 9.00% | down 0.67 pts | ₹119 Cr | down ₹1.4 Cr | Trimmed |
| Cipla Limited | 8.59% | up 1.41 pts | ₹113 Cr | up ₹24.2 Cr | Added |
| Dr. Reddy's Laboratories Limited | 7.43% | down 1.61 pts | ₹98.2 Cr | down ₹14.3 Cr | Trimmed |
| IPCA Laboratories Limited | 7.04% | down 1.09 pts | ₹93 Cr | down ₹8.1 Cr | Trimmed |
| FDC Limited | 3.43% | up 0.14 pts | ₹45.4 Cr | up ₹4.4 Cr | Added |
| Indoco Remedies Limited | 2.80% | down 0.35 pts | ₹37 Cr | down ₹2.2 Cr | Trimmed |
| Biocon Limited | 2.25% | down 0.16 pts | ₹29.7 Cr | down ₹24 L | Trimmed |
| Cash, TREPS & receivables | 1.91% | up 0.84 pts | ₹25.3 Cr | up ₹12 Cr | Added |
| Procter & Gamble Health Limited | 1.65% | down 0.56 pts | ₹21.9 Cr | down ₹5.7 Cr | Trimmed |
| Syngene International Limited | 1.51% | up 1.51 pts | ₹20 Cr | up ₹20 Cr | New |
What changed, Jun 2015 to Jul 2015
New New positions (1)
- Syngene International Limited1.5% · ₹20 Cr
Exited Exited (0)
None.
Added Biggest additions
- Sanofi India Limitedup ₹29.7 Cr (+1.73% pts)
- Cipla Limitedup ₹24.2 Cr (+1.41% pts)
- Abbott India Limitedup ₹19.6 Cr (+0.77% pts)
- Divi's Laboratories Limitedup ₹5.2 Cr (−0.17% pts)
Sectors
Which sectors the fund is moving towards and away from, and where its money sits now. Shares are of the fund’s classified equity holdings, so they add up to 100%.
Where the weight moved
Compared with
Since Jun 2015, the weight rose most in Healthcare Services (+1.5 pts), and fell most in Pharmaceuticals & Biotechnology (−1.2 pts) and Pharmaceuticals (−0.3 pts).
- Healthcare Services0.0% → 1.5%new+1.5 pts
- Pharmaceuticals & Biotechnology96.8% → 95.6%−1.2 pts
- Pharmaceuticals3.2% → 2.9%−0.3 pts
A sector’s weight changes when the fund buys or sells, and also when its shares rise or fall in price, so a change is not by itself a sign of buying or selling.
Main sectors’ weights over time
| Sector | Jul 2014 | Jan 2015 | Apr 2015 | Jun 2015 | Jul 2015 |
|---|---|---|---|---|---|
| Pharmaceuticals & Biotechnology | 94.0% | 92.6% | 96.2% | 96.8% | 95.6% |
| Pharmaceuticals | 4.9% | 6.8% | 3.3% | 3.2% | 2.9% |
| Healthcare Services | — | — | — | — | 1.5% |
Allocation in Jul 2015change vs Jun 2015
- Pharmaceuticals & Biotechnology (12)95.6%▼ 1.2 pts
- Pharmaceuticals (1)2.9%▼ 0.3 pts
- Healthcare Services (1)1.5%▲ 1.5 pts
Cash and debt
The share of the portfolio not in shares: cash and net receivables, money-market instruments and bonds, as disclosed each month. Cash can dip below zero when payables, often on derivative positions, exceed it. A change here describes what the fund did; it is not a signal. More on reading cash.
Cash & debt, Jul 2015
1.9%
▲ 0.8 pts vs Jun 2015
- Cash alone
- 1.9%
- cash and net receivables
- A year earlier
- 1.3%
- Jul 2014 · now ▲ 0.7 pts
- Last 12 months
- 0.2% – 3.0%
- lowest to highest · record 3.0% in Jan 2015
History
Disclosed portfolio value by month, with the stocks the fund entered and exited against its previous disclosure. Every month is a link to that portfolio.